News | May 02, 2026
Merck posts mixed Q1 2026 results as blockbuster drugs drive growth
But acquisition charges drag earnings into loss
But acquisition charges drag earnings into loss
The transaction marks a clear portfolio reshuffle for Indoco
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus
With the convergence of AI, robotics, and neuroscience, Motorica is advancing toward more intuitive, intent-driven prosthetic systems
The Danish biotech company confirmed the global study will begin in the second half of 2026
Health innovations are viewed more positively than food and agricultural technologies
Union health minister urges graduates in Chandigarh to combine technological excellence with compassion in medical practice
Subscribe To Our Newsletter & Stay Updated
